Ποια είναι η τιμή για Simcere Pharmaceutical Group Limited (2096)

Η τιμή για Simcere Pharmaceutical Group Limited (2096) είναι $1.48

Ποια είναι η κεφαλαιοποίηση αγοράς για Simcere Pharmaceutical Group Limited (2096)

Η κεφαλαιοποίηση αγοράς για Simcere Pharmaceutical Group Limited (2096) είναι $3.81B

Simcere Pharmaceutical Group Limited (2096) Διαίρεση Μετοχών

Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-Aß). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.